Skip to main content
SpringerLink
Log in

Risk Factors, Interventions and Therapeutic Agents in the Prevention of Atherosclerosis-Related Ischaemic Diseases

  • Section 2
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Of the major risk factors for atherosclerosis, high factor VII and fibrinogen levels, genetic predisposition, gender and age cannot be influenced. Reduction of high blood pressure reduces the cerebral but not the coronary vascular risk and correction of dyslipidaemia correlates with cardiovascular risk. Other major risk factors (tobacco consumption, obesity, sedentary lifestyle and diabetes) can also be modified.

Aspirin in doses of approximately 300 mg/day may be recommended for the primary prevention of myocardial infarction (MI), but only in those patients with a moderate to high risk of cardiovascular disease. Aspirin reduces the risk of fatal and nonfatal MI by about 50% and also decreases the overall mortality rate among patients with unstable angina. A lower dose of aspirin (150 mg/day) also reduces mortality by 23% in the acute phase of MI. In doses of 300 mg/day, aspirin is useful in the secondary prevention of MI and reduces the overall mortality rate by 15%.

Various antiplatelet agents, including aspirin (alone or combined with dipyridamole) and ticlopidine, have proved useful in the prevention of thrombosis in aorto-coronary grafts, provided treatment begins at the latest 6 hours after surgery. The usefulness of antiplatelet drugs has been well established in the prevention of immediate reocclusion following coronary angioplasty, but not in the prevention of late reocclusion. Aspirin and ticlopidine are also beneficial in extracorporeal circulation techniques. In patients with a synthetic cardiac valve prosthesis, antivitamin K-anticoagulants are still indispensable lifelong, but their antithrombotic effect can be reinforced by dipyridamole or aspirin.

Diuretics probably provide the best primary protection against cerebrovascular accidents, although medium doses of aspirin may be considered in elderly people at high risk of such accidents. Aspirin (alone or combined with dipyridamole) and ticlopidine may be recommended for the secondary prevention of cerebral ischaemic accidents.

Aspirin (with or without dipyridamole) and ticlopidine reinforce the treatment of obliterative arterial disease in the lower limbs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aberg A, Bergstrand R, Johansson S. Cessation of smoking after myocardial infarction. Effects on mortality after 10 years. British Heart Journal 49: 416–422, 1983

    PubMed  CAS  Google Scholar 

  • Altman R, Boullon F, Rouvier J, et al. Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. Journal of Thoracic Cardiovascular Surgery 72: 127–129, 1976

    CAS  Google Scholar 

  • Altman R,. Rouvier J, Gurfinkel E, et al. Comparison of two levels of anticoagulant therapy in patients with substitute heart valve. Journal of Thoracic Cardiovascular Surgery 101: 427–431, 1991

    CAS  Google Scholar 

  • Andrassy K, Malluche H, Bornefeld H, et al. Prevention of p.o. clotting of av. Cimino fistulae with acetylsalicylic acid. Results of a prospective double blind study. Klinische Wochenschrift 52: 348–349, 1974

    PubMed  CAS  Google Scholar 

  • Antiplatelet Trialists’ Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. British Medical Journal 296: 320–331, 1988

    Google Scholar 

  • Antiplatelet Trialists’ Collaboration. Second Main Meeting. Methods and Results, pp. 58–65, Oxford, March 1990. Lancet, in press, 1991

    Google Scholar 

  • Arcan JC, Blanchard J, Boissel JP, Destors JM, Panak E. Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Angiology 39: 802–811, 1988

    PubMed  CAS  Google Scholar 

  • Badimon JJ, Ip J, Badimon L, Fuster V. Thrombosis and accelerated atherosclerosis in coronary bypass surgery and restenosis after percutaneous transluminal coronary angioplasty: implications for therapy. Coronary Artery Disease 1: 170–179, 1990

    Google Scholar 

  • Balsano F, Coccheri S, Libretti A, et al. Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. Journal of Laboratory and Clinical Medicine 114: 84–91, 1989

    PubMed  CAS  Google Scholar 

  • Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. Circulation 82: 17–26, 1990

    PubMed  CAS  Google Scholar 

  • Barnathan ES, Schwartz JS, Taylor L, et al. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 76: 125–134, 1987

    PubMed  CAS  Google Scholar 

  • Berglund U, Wallentin L. Persistent inhibition of platelet function during long-term treatment with 75mg acetylsalicylic acid daily in men with unstable coronary artery disease. European Heart Journal 12: 428–433, 1991

    PubMed  CAS  Google Scholar 

  • Bertrand ME, Allain H, Lablanche JM. Results of a randomized trial of ticlopidine versus placebo for prevention of acute closure and restenosis after coronary angioplasty (PTCA). Abstract. Circulation 82: III–190, 1990

    Google Scholar 

  • Boissel JP, Peyrieux JC, Destors JM. Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs? Thrombosis and Haemostasis 62: 681–685, 1989

    PubMed  CAS  Google Scholar 

  • Boysen G, Boss AH, Odum N, Olsen JS. Prolongation of bleeding time and inhibition of platelet aggregation by low-dose acetylsalicylic acid in patients with cerebrovascular disease. Stroke 15: 241–243, 1984

    PubMed  CAS  Google Scholar 

  • Brown BG, Cuckingnan RA, De Rouen T. Improved graft-patency on patients treated with platelet inhibiting therapy following coronary bypass surgery. Circulation 72: 138–146, 1985

    PubMed  CAS  Google Scholar 

  • Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. New England Journal of Medicine 313: 1369–1375, 1985

    PubMed  CAS  Google Scholar 

  • Chalmers TC, Matta RJ, Smith H, Kunzler AM. Evidence favouring the use of anticoagulants in the hospital phase of acute myocardial infarction. New England Journal of Medicine 297: 1091–1096, 1977

    PubMed  CAS  Google Scholar 

  • Chesebro JH, Clements IP, Fuster V, et al. A platelet-inhibitor drug trial in coronary artery bypass operations. Benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. New England Journal of Medicine 307: 73–78, 1982

    PubMed  CAS  Google Scholar 

  • Chesebro JH, Fuster V, Elveback R, et al. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. New England Journal of Medicine 310: 209–214, 1984

    PubMed  CAS  Google Scholar 

  • Chesebro JH, Fuster V, Halperin JL. Atrial fibrillation-risk marker for stroke. New England Journal of Medicine 323: 1556–1558, 1990

    PubMed  CAS  Google Scholar 

  • Chesebro JH, Webster MWI, Reeder GS, et al. Coronary angioplasty: antiplatelet therapy reduces acute complications but not restenosis. Abstract. Circulation 80(Suppl. II): 64, 1989b

    Google Scholar 

  • Chesebro JH, Webster WI, Smith HC, et al. Antiplatelet therapy in coronary disease progression: reduced infarction and new lesion formation. Abstract. Circulation 80(Suppl. II): 266, 1989a

    Google Scholar 

  • Chevigné M, David JL, Rigo P, Limet R. Effect of ticlopidine on saphenous vein patency: a double-blind study. Annals of Thoracic Surgery 37: 371–378, 1984

    PubMed  Google Scholar 

  • Cloarec M, Caillard Ph, Mouren X. Double-blind clinical trial of ticlopidine versus placebo in peripheral atherosclerotic disease of the legs. Angiologie (Suppl. 77): 14–20, 1988

    Google Scholar 

  • Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 335: 827–838, 1990

    PubMed  CAS  Google Scholar 

  • Corcos T, David PR, Val PG, et al. Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty. American Heart Journal 169: 926–931, 1985

    Google Scholar 

  • Dale J, Myhre E, Storstein O, Stormorken H, Efskin DL. Prevention of arterial thromboembolism with acetylsalicylic acid: a controlled clinical study in patients with aortic ball valves. American Heart Journal 94: 101–111, 1977

    PubMed  CAS  Google Scholar 

  • Daly LE, Graham IM, Hickey N, Mulcahy R. Does stopping smoking delay onset of angina after infarction? British Medical Journal 291: 935–937, 1985

    PubMed  CAS  Google Scholar 

  • Danish Study Goup on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II — DAVIT II). American Journal of Cardiology 66: 779–785, 1990

    Google Scholar 

  • de Gaetano G, Cerletti C, Dejana E, Vermylen J. Current issues in thrombosis prevention with antiplatelet drugs. Drugs 31: 517–549, 1986

    PubMed  Google Scholar 

  • Dehmer GJ, Popma JJ, Van den Berg EK, et al. Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids. New England Journal of Medicine 319: 733–740, 1988

    PubMed  CAS  Google Scholar 

  • de Smit P, van Urk H. The effect of long-term treatment with oral anticoagulants in patients with peripheral vascular disease. In Tilsner V, Matthias FR (Eds) Arterielle Verschlusskrankheit und Blutgerinnung, pp. 211–217, Editiones ‘Roche’, 1987

    Google Scholar 

  • Ellis DJ, Eckhoff C. Prevention of cardiovascular events in patients with intermittent claudication: results of a therapeutic trial with ticlopidine. Angiology (Suppl. 77): 31–38, 1988

    Google Scholar 

  • Ellis SG, Roubin GS, Wilentz J, Douglas JS, King SB. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. American Heart Journal 117: 777–782, 1989

    PubMed  CAS  Google Scholar 

  • Elwood PC, Sweetnam PM. Aspirin and secondary mortality after myocardial infarction. Lancet 2: 1313–1315, 1979

    PubMed  CAS  Google Scholar 

  • Fagerstrom KO. Tolerance, withdrawal and dependence on tobacco and smoking termination. International Review of Applied Physiology 32: 29–52, 1983

    Google Scholar 

  • Finci L, Höfling B, Ludwig B, Bulitta M, Steffenino G, et al. Sulotroban during and after coronary angioplasty. A doubleblind, placebo controlled study. Zeitschrift für Kardiologie 78(Suppl. 3): 50–54, 1989

    PubMed  Google Scholar 

  • Fitzgerald GA. Dipyridamole. New England Journal of Medicine 316: 1247–1257, 1987

    PubMed  CAS  Google Scholar 

  • Gavaghan TP, Gebski V, Baron DW. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. Circulation 83: 1526–1533, 1991

    PubMed  CAS  Google Scholar 

  • Gavaghan TP, Hickie JB, Krilis SA, et al. Increased plasma beta-thromboglobulin in patients with coronary artery vein graft occlusion: response to low dose aspirin. Journal of the American College of Cardiology 15: 1250–1258, 1990

    PubMed  CAS  Google Scholar 

  • Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1: 1215–1520, 1989

    PubMed  CAS  Google Scholar 

  • Gent M, Blakely JA, Hachinski V, et al. A secondary prevention, randomized trial of suloctidil in patients with a recent history of thromboembolic stroke. Stroke 16: 416–424, 1985

    PubMed  CAS  Google Scholar 

  • Goldman S, Copeland J, Moritz T, et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation 77: 1324–1332, 1988a

    PubMed  CAS  Google Scholar 

  • Goldman S, Copeland J, Moritz T, et al. Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Circulation 80: 1190–1197, 1989

    PubMed  CAS  Google Scholar 

  • Goldman L, Sia B, Cook F, Rutherford JD, Weinstein MC. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. New England Journal of Medicine 319: 152–157, 1988b

    PubMed  CAS  Google Scholar 

  • Grigg LE, Kay TWH, Valentine PA. Determinants of restenosis and lack of effect of dietary supplementation with eicosapentaenoic acid on the incidence of coronary artery restenosis after angioplasty. Journal of the American College of Cardiology 13: 665–672, 1989

    PubMed  CAS  Google Scholar 

  • Grontoft K-C, Mulec H, Gutierrez A, Olander R. Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for hemodialysis. Scandinavian Journal of Urology and Nephrology 19: 55–57, 1985

    PubMed  CAS  Google Scholar 

  • Groupe de Recherche PACTE. Prévention des accidentes thromboemboliques systémiques chez les porteurs de prothesis valbulaires artificielles: essai cooperatif controle du dipyridamole. Coeur 9: 915–969, 1978

    Google Scholar 

  • Halperin JL, Petersen P. Thrombosis in cardiac chambers: ventricular dysfunction and atrial fibrillation. In Fuster V, Verstraete M (Eds) Thrombosis in Cardiovascular Disease, WB Saunders, in press, 1991

    Google Scholar 

  • Hamming JJ, Hensen A, Loeliger EA. The value of long-term coumarin treatment in peripheral sclerosis. Clinical trial (Abstract). Thrombosis and Diathesis Haemorrhagica 41: 405, 1965

    Google Scholar 

  • Hampson J, Barnes EW, Connolly CK, Trewby EW, Carr PH. Secondary prophylaxis against myocardial infarction. British Medical Journal 302: 656–657, 1991

    Google Scholar 

  • Harker LA, Slichter SJ. Platelet and fibrinogen consumption in man. New England Journal of Medicine 287: 999–1005, 1972

    PubMed  CAS  Google Scholar 

  • Harter HR, Burch JW, Majerus PW, et al. Prevention of thrombosis in patients on haemodialysis by low dose aspirin. New England Journal of Medicine 301: 577–579, 1979

    PubMed  CAS  Google Scholar 

  • Hass WK, Easton JD, Adame HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. New England Journal of Medicine 321: 501–507, 1989

    PubMed  CAS  Google Scholar 

  • Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. British Medical Journal 299: 1187–1192, 1989

    PubMed  CAS  Google Scholar 

  • Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 80: 749–756, 1989

    PubMed  CAS  Google Scholar 

  • Hennekens CH, Karlson LK, Rasner B. A case-control study of regular aspirin use and coronary deaths. Circulation 58: 35–38, 1978

    PubMed  CAS  Google Scholar 

  • Hennekens CH, Peto R, Hutchinson GB, et al. An overview of the British and American aspirin studies. New England Journal of Medicine 318: 923–924, 1988

    PubMed  CAS  Google Scholar 

  • Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of platelet function delays progression of periphefal occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Lancet 1: 415–419, 1985

    PubMed  CAS  Google Scholar 

  • Hostmark AT, Bjerkedal T, Kierulf P, Flaten H, Ulshagen K. Fish oil and plasma fibrinogen. British Medical Journal 297: 180–181, 1988

    PubMed  CAS  Google Scholar 

  • Installé E, Gonzales M, Schoevaerdts JC, Tremouroux J. Prevention by ticlopidine of platelet consumption during extra-corporeal circulation for heart surgery and lack of effect on operative and postoperative bleeding. Journal of Cardiovascular Pharmacology 3: 1174–1183, 1981

    PubMed  Google Scholar 

  • ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither amongst 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2: 349–360, 1988

    Google Scholar 

  • Janzon L, Bergqvist D, Boberg J, Boberg M, Eriksson I, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication: effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. Journal of Internal Medicine 227: 301–308, 1990

    PubMed  CAS  Google Scholar 

  • Jarvik ME, Schneider NG. Degree of addiction and effectiveness of nicotine gum therapy for smoking. American Journal of Psychiatry 141: 790–791, 1984

    PubMed  CAS  Google Scholar 

  • Jugdatt BI, Warnica JW. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications: effect of timing, dosage, and infarct location. Circulation 78: 906–919, 1988

    Google Scholar 

  • Kasahara T. Clinical effect of dipyridamole ingestion after prosthetic heart valve replacement — especially on the blood coagulation system. Journal of the Japanese Association of Thoracic Surgery 25: 1007–1021, 1977

    CAS  Google Scholar 

  • Kobayashi K, Malda K, Koshikawa S, et al. Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis (2). Multicenter collaborative double blind study. Igaku No Ayumi 112: 294–308, 1980

    Google Scholar 

  • Kretschmer G, Wenzl E, Schemper M, et al. Influence of postoperative anticoagulant treatment on patient survival after femoropopliteal vein bypass surgery. Lancet 1: 797–799, 1988

    PubMed  CAS  Google Scholar 

  • Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. New England Journal of Medicine 309: 396–403, 1983

    PubMed  Google Scholar 

  • Limbo NJ, Black AJ, Roubin GS. Does the addition of dipyridamole to aspirin decrease acute coronary angioplasty complications? The results of a prospective randomized trial. Abstract. Journal of the American College of Cardiology 11(Suppl. A): 237A, 1988

    Google Scholar 

  • Limet R, David JL, Magotteaux P, La Rock MP, Rigo P. Prevention of aortocoronary bypass graft occlusion: beneficial effect of ticlopidine on early and late patency rates of venous-coronary bypass grafts: a double-blind study. Journal of Thoracic and Cardiovascular Surgery 94: 773–783, 1987

    PubMed  CAS  Google Scholar 

  • Lorenz RL, Schacky CV, Weber M, et al. Improved aortocoronary bypass patency by low-dose aspirin (100mg daily). Lancet 1: 1261–1264, 1984

    PubMed  CAS  Google Scholar 

  • Lundergan CF, Foegh ML, Ramwell PW. Peptide inhibition of myointimal proliferation by angiopeptin, a somatostatin analogue. Journal of the American College of Cardiology 17: 132B–136B, 1991

    PubMed  CAS  Google Scholar 

  • MacMahon S, Peto R, Cutter J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335: 765–774, 1990

    PubMed  CAS  Google Scholar 

  • Manson JE, Grobbee DE, Stampfer MJ. Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians. American Journal of Medicine 89: 772–776, 1990

    PubMed  CAS  Google Scholar 

  • Mayo NE, Levy AR. Aspirin and prevention of myocardial infarction. Lancet 330: 1069, 1990

    Google Scholar 

  • Milner MR, Gallino RA, Leffingwell A, et al. Usefulness of fish oil supplements in preventing clinical evidence of restenosis after percutaneous transluminal coronary angioplasty. American Journal of Cardiology 64: 294–299, 1989

    PubMed  CAS  Google Scholar 

  • Molitch ME. The evolution of artificial heart valves. New England Journal of Medicine 324: 624–627, 1991

    Google Scholar 

  • Mortel KF, Funk JL, Meyer JS, Vanek L. Cerebral perfusion and cognitive effects of aspirin versus ticlopidine in patients with cerebral ischaemia. Drug Investigation 3: 61–68, 1991

    Google Scholar 

  • Moss AJ, Benhorin J. Prognosis and management after a first myocardial infarction. New England Journal of Medicine 322: 743–753, 1990

    PubMed  CAS  Google Scholar 

  • Muller DWM, Ellis SG, Topol EJ. Colchicine and antineoplastic therapy for the prevention of restenosis after percutaneous coronary interventions. Journal of the American College of Cardiology 17: 126B–131B, 1991

    PubMed  CAS  Google Scholar 

  • Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. New England Journal of Medicine 319: 385–392, 1988

    Google Scholar 

  • Neri Serneri GG, Gensini GF, Carnovali M, Rovelli F, Pirelli S, et al. Effectiveness of low-dose heparin in prevention of myocardial infarction. Lancet 1: 937–941, 1987

    PubMed  CAS  Google Scholar 

  • Neri Serneri GG, Gensini GF, Poggesi L, et al. Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina. Lancet 335: 615–618, 1990

    PubMed  CAS  Google Scholar 

  • O’Keefe JH, Giorgi LV, Hartzler GO, et al. Effects of diltiazem on complications and restenosis after coronary angioplasty. American Journal of Cardiology 67: 373–376, 1991a

    PubMed  Google Scholar 

  • O’Keefe JH, McCallister BD, Bateman TM, Kuhnelein D, Ligon RW, et al. Colchicine for the prevention of restenosis after coronary angioplasty. Abstract. Journal of the American College of Cardiology 17: 181A, 1991b

    Google Scholar 

  • Oliver MF. Might treatment of hypercholesterolaemia increase non-cardiac mortality. Lancet 337: 1529–1531, 1991

    PubMed  CAS  Google Scholar 

  • Olsson G, Levin L-A, Rehnqvist N. Economic consequences of postinfarction prophylaxis with beta blockers: cost effectiveness of metoprolol. British Medical Journal 294: 339–342, 1987

    PubMed  CAS  Google Scholar 

  • Petersen P. Thromboembolic complications in atrial fibrillation. Stroke 21: 4–13, 1990

    PubMed  CAS  Google Scholar 

  • Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. British Medical Journal 296: 13–16, 1988

    Google Scholar 

  • Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilation after anterior myocardial infarction. New England Journal of Medicine 319: 80–86, 1988

    PubMed  CAS  Google Scholar 

  • Pfisterer M, Burkart F, Jockers G, et al. Trial of low-dose aspirin plus anticoagulants for prevention of aortocoronary vein graft occlusion. Lancet 2: 1–7, 1989

    PubMed  CAS  Google Scholar 

  • Popma JJ, Dehmer GJ. Care of patient after coronary angioplasty. Annals of Internal Medicine 110: 547–559, 1989

    PubMed  CAS  Google Scholar 

  • Prevention of Atherosclerotic Complications with Ketanserin (PACK) Trial Group. Prevention of atherosclerotic complications: controlled trial of ketanserin. British Medical Journal 298: 424–430, 1989

    Google Scholar 

  • Rajah SM, Sreeharan N, Joseph A, et al. A prospective trial of dipyridamole and warfarin in heart valve patients. Abstract. Acta Therapeutica 6(Suppl. 93): 54, 1980

    Google Scholar 

  • Reis GJ, Boucher TM, Sipperly ME, et al. Randomised trial of fish oil for prevention of restenosis after coronary angioplasty. Lancet 2: 177–186, 1989

    PubMed  CAS  Google Scholar 

  • Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Archives of Internal Medicine 148: 36–69, 1988

    Google Scholar 

  • Ridker PM, Manson JE, Gaziano JM, Buring JE, Hennekens CH. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. Annals of Internal Medicine 114: 835–839, 1991

    PubMed  CAS  Google Scholar 

  • RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men during unstable coronary artery disease. Lancet 336: 827–830, 1990

    Google Scholar 

  • Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. New England Journal of Medicine 323: 1112–1119, 1990

    PubMed  CAS  Google Scholar 

  • Rothlin ME, Pfluger M, Speiser K, et al. Platelet inhibitors versus anticoagulants for prevention of aorto-coronary bypass graft occlusion. European Heart Journal 6: 168–175, 1985

    PubMed  CAS  Google Scholar 

  • Rowe GG, Folts JD. Aspirin and dipyridamole and their limitations in the therapy of coronary artery disease. Clinical Cardiology 13: 165–170, 1990

    PubMed  CAS  Google Scholar 

  • Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 89(Suppl. 2): 2S–3S, 1986

    PubMed  CAS  Google Scholar 

  • Sahni R, Maniet QR, Voci G, Banka VS. Prevention of restenosis by lovastatin after successful coronary angioplasty. American Heart Journal 121: 1600–1608, 1991

    PubMed  CAS  Google Scholar 

  • Sanz G, Pajaron A, Alegria E, et al. Prevention of early aortocoronary bypass occlusion by low-dose aspirin and dipyridamole. Circulation 82: 765–773, 1990

    PubMed  CAS  Google Scholar 

  • Schlant RC, Forman S, Stamler J, Canner PL. The natural history of coronary heart disease: prognostic factors after recovery from myocardial infarction in 2789 men: the 5-year findings of the Coronary Drug Project. Circulation 66: 401–414, 1982

    PubMed  CAS  Google Scholar 

  • Schoop W, Levy H, Schoop B, Gaentsch A. Experimentelle und klinische Studien zu der sekundären Prävention der peripheren Arteriosklerose. In Bollinger A, Rhyner K (Eds) Thrornbozytenfunktionshemmer, pp. 49–58, George Thieme Verlag, Stuttgart, 1983

    Google Scholar 

  • Schwartz L, Bourassa MG, Lespérance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal angioplasty. New England Journal of Medicine 318: 1714–1719, 1988a

    PubMed  CAS  Google Scholar 

  • Schwartz L, Bourassa MG, Lespérance J, et al. Failure of antiplatelet agents to reduce restenosis after PTCA in a double blind placebo controlled trial. Abstract. Journal of the American College of Cardiology 11: 236A, 1988b

    Google Scholar 

  • Secondary prevention of coronary disease with lipid-lowering drugs. Lancet 1: 473–474, 1989

  • Sethi GK, Copeland JG, Goldman S, Moritz T, et al. and Participants in the Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy. Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Journal of the American College of Cardiology 15: 15–20, 1990

    PubMed  CAS  Google Scholar 

  • Sherman DG, Dyken ML, Fisher M, Harrison MJG, Hart RG. Cerebral embolism. Chest 89 (Suppl.): 82S–98S, 1986

    PubMed  CAS  Google Scholar 

  • Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 2: 989–993, 1980

    Google Scholar 

  • Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. New England Journal of Medicine 323: 147–152, 1990

    PubMed  CAS  Google Scholar 

  • Steele P, Rainwater J, Vogel R. Platelet suppressant therapy in patients with prosthetic cardiac valves: relationship of clinical effectiveness to alteration of platelet survival time. Circulation 60: 910–913, 1979

    PubMed  CAS  Google Scholar 

  • Steering Committee of the Physicians’ Health Study Research Group. Findings from the aspirin component of the ongoing Physicians’ Health Study. New England Journal of Medicine 318: 262–264, 1988

    Google Scholar 

  • Steering Committe of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. New England Journal of Medicine 321: 129–135, 1989

    Google Scholar 

  • Stiegler H, Hess H, Mietaschk A, Tramppisch HJ, Ingrisch H. Einfluss von Ticlopidin auf die peripher oblitierende Arteriopathie. Deutsche Medizinische Wochenschrift 109: 1240–1243, 1984

    PubMed  CAS  Google Scholar 

  • Svensson J, Samuelsson K. Inhibition of platelet function by low dose acetylsalicylic acid in patients with cerebrovascular disease. Thrombosis Research 31: 499–505, 1983

    PubMed  CAS  Google Scholar 

  • Swedish Cooperative Study Group. High dose acetylsalicylic acid after infarction. Stroke 118: 325–334, 1987

    Google Scholar 

  • Szekely P. Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease. British Medical Journal 1: 1209–1212, 1964

    PubMed  CAS  Google Scholar 

  • Théroux P, Quimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. New England Journal of Medicine 319: 1105–1111, 1988

    PubMed  Google Scholar 

  • Thorton MA, Gruentzig AR, Hollman J, King SB III, Douglas JS. Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: a randomized study. Circulation 69: 721–727, 1984

    Google Scholar 

  • TIMI Study Group. Comparison of invasive and conservative strategies with intravenous tissue-type plasminogen activator in acute myocardial infarction. New England Journal of Medicine 320: 618–627, 1989

    Google Scholar 

  • Turpie AGG, Gunstensen J, Hirsh J, et al. Randomized comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1: 1242–1245, 1988

    PubMed  CAS  Google Scholar 

  • Turpie AGG, Robinson JG, Doyle DG, et al. Comparison of high-dose with low-dose subcutaneous heparin in the prevention of left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. New England Journal of Medicine 320: 352–357, 1989

    PubMed  CAS  Google Scholar 

  • UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. British Medical Journal 296: 316–320, 1988

    Google Scholar 

  • Urban P, Buller N, Fox K, Shapiro L, Bayliss J, et al. Lack of effect of warfarin on the restenosis rate or on clinical outcome after balloon coronary angioplasty. British Heart Journal 60: 485–488, 1988

    PubMed  CAS  Google Scholar 

  • Verstraete M, Brown BG, Chesebro JH, et al. Evaluation of antiplatelet agents in the prevention of aorto-coronary bypass occlusion. European Heart Journal 7: 4–13, 1986

    PubMed  CAS  Google Scholar 

  • Visser CA, Kan G, Meltzer RS, Lie KI. Long-term follow-up of left ventricular thrombus after acute myocardial infarction: a two-dimensional echocardiographic study in 96 patients. Chest 86: 532–536, 1984

    PubMed  CAS  Google Scholar 

  • White CW, Knudsen M, Schmidt D, et al. Neither ticlopidine nor aspirin-dipyridamole prevents restenosis post PTCA: results from a randomized placebo-controlled multicenter trial. Abstract. Circulation 76(Suppl. IV): 213, 1987

    Google Scholar 

  • Whiteworth HB, Roubin GS, Hollman J, et al. Effect of nifedipine on recurrent stenosis after percutaneous transluminal coronary angioplasty. Journal of the American College of Cardiology 8: 1271–1276, 1986

    Google Scholar 

  • Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of randomized trials. Progress in Cardiovascular Disease 27: 355–371, 1985

    Google Scholar 

  • Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. Journal of the American Medical Association 260: 2088–2093, 1988a

    PubMed  CAS  Google Scholar 

  • Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. Journal of the American Medical Association 260: 2259–2563, 1988b

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium

    M. Verstraete (Professor of Medicine)

Authors
  1. M. Verstraete
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Verstraete, M. Risk Factors, Interventions and Therapeutic Agents in the Prevention of Atherosclerosis-Related Ischaemic Diseases. Drugs 42 (Suppl 5), 22–38 (1991). https://doi.org/10.2165/00003495-199100425-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199100425-00006

Keywords

Search

Navigation